Late-stage trial data is showing that some Covid-19 vaccines are reducing people’s risk for hospitalization (and even death) from the Coronavirus. We curated some of the latest research, data, and studies for you to learn more about these findings.

• New data from Scotland is reporting that from December 8, 2020, to February 15, 2021, 1.14M people received the Covid-19 vaccine. That means 21 percent of the Scottish population received their first dose. To summarize this study, researchers compared the outcomes of those who received their first dose of the vaccine to those who did not. By the fourth week of the initial dose, the Pfizer and Oxford-AstraZeneca vaccines showed a reduction in the risk of hospitalizations from Covid-19 in 85 to 94 percent of people. After four weeks of that population receiving both doses, those who were 80 years and older showed an 81 percent reduction in hospitalization risk.

• AstraZeneca’s Covid-19 vaccine confirmed a 100 percent protection rate against severe disease, hospitalization, and death in their primary analysis of phase 3 trials in the UK, Brazil, and South Africa. Data from this study showed a 76 percent efficacy after the first dose with maintained protection until the second dose. Efficacy increased to 82 percent with an inter-dose interval of 12 weeks or more. This study included 17,177 participants.

• Late-stage trials of the CoronaVac Covid-19 vaccine showed a 100 percent effective rate in preventing patients with the Coronavirus from being hospitalized or dying and an 83.7 percent effective rate in avoiding cases that required medical treatment. However, there was only a 50.65 percent effective rate of this vaccine keeping people from getting infected. This trial included 12,396 people and evaluated the candidates, who received two-shot vaccines, 14 days after receiving these doses. The CoronaVac was also tested in two stages in Turkey and was found to have a 91.25 percent efficacy rate in preventing Covid-19 based on an analysis of 29 cases.

• Currently, the two authorized Covid-19 vaccines to be used in the United States have shown to be 95 percent effective in preventing illness in the late-state trials. These vaccines are developed by Pfizer and BioNTech, and Moderna Inc.

• In Israel, researchers are finding the Covid-19 vaccine to curb infections and hospitalizations among people 60 and older after 6 weeks of the vaccine being rolled out. Close to 90 percent of the population in Israel who are ages 60 and above received their first of two doses of the Pfizer vaccine. According to data from Israel’s Ministry of Health, there was a 41 percent drop in confirmed Covid-19 cases in that age group and a 31 percent drop in hospitalizations from mid-January to early February. For people 59 and younger who were vaccinated, Covid-19 infection cases dropped by only 12 percent and hospitalizations by 5 percent over the same amount of time. The data provided was based on roughly a quarter of a million Covid-19 cases.

If you have questions about the Covid-19 vaccine for your long-term care facility, please reach out to our team. Call us at 845 341-2700 or contact us online.